Neither phosphatidylserine nor citicoline has been compared head-to-head in rigorous trials, and neither is supported by evidence sufficient to claim dementia risk reduction. A 2026 systematic review found current evidence does not support either compound as an effective cognitive enhancer in neurological disorders. Both show modest, inconstant effects at best in supportive roles—not as monotherapy or prevention strategies.
The apparent promise of each rests on different problems. Phosphatidylserine's dementia evidence comes from trials using bovine-brain extract (no longer available), while modern plant-derived versions show weaker results. Citicoline has never been tested in large randomized trials for dementia at all. Understanding what each trial actually measured, and what was lost in translation to today's supplements, is essential before interpreting claims or making a decision.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why Phosphatidylserine's Evidence Does Not Transfer to Today's Supplements
- Citicoline's Evidence Gap: No Large Trials, No FDA Approval
- Safety: Both Are Tolerated, But Long-Term Data Are Sparse
- Why a Direct Comparison Fails
- What This Means When Dementia Care Decisions Are Real
- Frequently Asked Questions
Why Phosphatidylserine's Evidence Does Not Transfer to Today's Supplements
Phosphatidylserine's reputation rests on eleven older randomized placebo-controlled trials conducted in the late 1980s and mid-1990s. These studies used bovine cortex phosphatidylserine at 300 mg/day and reported cognitive improvements in Alzheimer's patients. However, bovine-derived phosphatidylserine is no longer available due to BSE (mad cow disease) safety concerns, according to the Alzheimer's Drug Discovery Foundation's Cognitive Vitality ratings. Today's supplements use plant-derived phosphatidylserine, which is chemically different in ways that matter.
Bovine phosphatidylserine contains primarily stearic and oleic acids, while plant-derived phosphatidylserine is rich in linoleic and palmitic acids. This compositional drift means the old trials may not apply to the products currently sold. When researchers pooled nine newer plant-based studies covering 961 participants in a 2022 meta-analysis, they found positive effects on memory in older adults—but the effect sizes were modest, and four of nine studies had bias concerns. The practical consequence: you cannot reliably assume that a modern supplement labeled "phosphatidylserine" behaves like the compounds tested in the 1990s. The evidence base has shifted, the source molecule has changed, and the effect size has contracted.
Citicoline's Evidence Gap: No Large Trials, No FDA Approval
Citicoline has never undergone the rigorous testing reserved for dementia treatments. Citicoline lacks FDA approval for cognitive disorders and has never been tested in large randomized controlled trials for dementia prevention or treatment. The FDA-approved agents for Alzheimer's (donepezil, galantamine, rivastigmine, memantine) all have this approval because they cleared large, controlled trials. Citicoline has not.
The evidence for citicoline in dementia is fragmentary. Seven case-control observational studies suggest citicoline *may* improve cognition when added to standard Alzheimer's treatments, but observational designs cannot rule out confounding or placebo effects. One small randomized trial and four non-controlled open-label studies exist, but small, uncontrolled trials cannot establish whether a drug works—they can only hint that it might be worth testing more rigorously. Pilot trials show promise for memory and reaction time in limited samples, but effects are small and appear limited to adjunctive use (added to existing treatment) rather than as a standalone therapy. There is no prevention evidence for citicoline in healthy older adults or people at risk for dementia.
Safety: Both Are Tolerated, But Long-Term Data Are Sparse
Both supplements are generally well-tolerated, with similar mild side effects. The most common adverse events are gastrointestinal discomfort (nausea, diarrhea, stomach upset) and headache; serious adverse events are rare. Phosphatidylserine at doses above 300 mg/day may cause insomnia.
Neither has demonstrated long-term safety beyond 6–12 months in published studies. Neither compound poses an immediate safety crisis at standard doses. However, the safety profile does not compensate for the lack of efficacy evidence—a well-tolerated placebo is still a placebo.
Why a Direct Comparison Fails
You might hope for a simple answer: "Take this one instead." That is not possible because the trials, populations, and chemical formulations are too different. Phosphatidylserine's composition varied widely between studies, limiting the ability to combine findings or apply older data to current supplements.
Citicoline's evidence comes from small, mostly observational studies in people who already have cognitive decline, not from trials of prevention or treatment in isolation. Head-to-head trials would be needed to identify a genuine superiority. None exist, and neither supplement's current evidence base is strong enough to justify the expense of running such a trial.
What This Means When Dementia Care Decisions Are Real
If you or a family member is considering either supplement as part of dementia care, the evidence does not support using either as a primary strategy. If a physician suggests adding citicoline to a standard Alzheimer's medication, observational data suggest it *may* contribute a small additional benefit—but this remains unproven. Phosphatidylserine is less likely to help because modern plant-derived forms have not been adequately tested in people with dementia.
For dementia prevention in cognitively healthy older adults, neither supplement has evidence sufficient to justify routine use. The agents with the strongest prevention evidence are physical activity, cognitive engagement, and management of cardiovascular risk factors (blood pressure, cholesterol, diabetes). If you are exploring supplements, discuss any addition with your neurologist or geriatrician to ensure it does not interfere with prescribed medications or displace more effective interventions.
Frequently Asked Questions
Can I take both together?
No trial has tested this combination. Both are tolerated individually, but using unproven supplements together increases the risk of side effects without added evidence of benefit.
If my doctor prescribed citicoline, should I stop?
No. If your physician recommended it as an adjunct to standard Alzheimer's medication, follow their guidance. Discuss any concerns about efficacy or safety with them directly rather than stopping on your own.
Are there supplements with better dementia evidence?
Cognitive Vitality rates ginkgo biloba as "insufficient evidence"—a similar weakness to phosphatidylserine and citicoline. The strongest evidence supports non-supplement interventions: exercise, cognitive engagement, sleep, and cardiovascular health.
